Adicet Bio Reports Third Quarter 2026 Financial Results and Business Updates
Adicet Bio announced its financial results for the third quarter of 2026, reporting a reduced net loss and providing updates on its clinical development programs.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Adicet Bio announced its financial results for the third quarter of 2026, reporting a reduced net loss and providing updates on its clinical development programs.
Filed: 2026-11-05 AccNo: 0001720580-26-000065 Size: 378 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Adicet Bio, Inc. announced the grant of a non-qualified stock option to a new employee as an inducement award.
Adicet Bio, Inc. announced that its management team will participate in two investor conferences scheduled for November 2026.
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.
HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the price target from $27 to $34.